- Home
- ADPT vs NDMO Comparison
ADPT vs NDMO Comparison
Compare ADPT & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- NDMO
- Stock Information
- Founded
- ADPT 2009
- NDMO 2019
- Country
- ADPT United States
- NDMO United States
- Employees
- ADPT 709
- NDMO N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- NDMO Trusts Except Educational Religious and Charitable
- Sector
- ADPT Health Care
- NDMO Finance
- Exchange
- ADPT Nasdaq
- NDMO Nasdaq
- Market Cap
- ADPT 749.7M
- NDMO 661.7M
- IPO Year
- ADPT 2019
- NDMO N/A
- Fundamental
- Price
- ADPT $5.08
- NDMO $10.62
- Analyst Decision
- ADPT Buy
- NDMO
- Analyst Count
- ADPT 4
- NDMO 0
- Target Price
- ADPT $6.50
- NDMO N/A
- AVG Volume (30 Days)
- ADPT 1.1M
- NDMO 218.6K
- Earning Date
- ADPT 11-07-2024
- NDMO 01-01-0001
- Dividend Yield
- ADPT N/A
- NDMO 6.75%
- EPS Growth
- ADPT N/A
- NDMO N/A
- EPS
- ADPT N/A
- NDMO N/A
- Revenue
- ADPT $177,282,000.00
- NDMO N/A
- Revenue This Year
- ADPT $3.82
- NDMO N/A
- Revenue Next Year
- ADPT $20.38
- NDMO N/A
- P/E Ratio
- ADPT N/A
- NDMO N/A
- Revenue Growth
- ADPT N/A
- NDMO N/A
- 52 Week Low
- ADPT $2.28
- NDMO $8.99
- 52 Week High
- ADPT $6.70
- NDMO $11.24
- Technical
- Relative Strength Index (RSI)
- ADPT 47.04
- NDMO 37.09
- Support Level
- ADPT $5.09
- NDMO $10.62
- Resistance Level
- ADPT $6.70
- NDMO $10.77
- Average True Range (ATR)
- ADPT 0.46
- NDMO 0.13
- MACD
- ADPT 0.00
- NDMO 0.00
- Stochastic Oscillator
- ADPT 24.48
- NDMO 15.28
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. The investment objective of the Fund is to seek total return through income exempt from regular federal income taxes and capital appreciation.